Skip to main content

Advertisement

Table 1 Clinical and histopathological characteristics of patients and their respective tumours

From: Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

  All eligible patients n = 34 Good responders n =17 Poor responders n =17 p-value
Age Mean 58.6 58.0 59.2 0.07
Gender Female 14 (41%) 5 (29%) 9 (53%) 0.30
Male 20 (59%) 12 (71%) 8 (47%)
Number of metastatic sites 1 17 (50%) 9 (53%) 8 (47%) 0.60
>1 17 (50%) 8 (47%) 9 (53%)
WHO PS 0 23 (68%) 11 (65%) 12 (71%) 0.71
1 11 (32%) 6 (35%) 5 (29%)
Site of primary tumour Colon 22 (65%) 11 (65%) 11 (65%) 0.90
Rectosigmoid 12 (35%) 6 (35%) 6 (35%)
T stage 1-2 4 (12%) 2 (12%) 2 (12%) 0.49
3 21 (62%) 12 (71%) 9 (53%)
4 9 (26%) 3 (18%) 6 (35%)
N stage 0 9 (26%) 4 (24%) 5 (29%) 0.61
1 8 (24%) 4 (24%) 4 (24%)
2 14 (41%) 9 (53%) 5 (29%)
Unknown 3 (9%) 0 3 (18%)
Differentiation grade Good 1 (3%) 1 (6%) 0 0.02
Moderate 23 (68%) 15 (88%) 8 (47%)
Poor 10 (29%) 1 (6%) 9 (53%)
  Wild-type 30 (88%) 16 (94%) 14 (82%) 0.29
  Mutant 4 (12%) 1 (6%) 3 (18%)
KRAS mutation status Wild-type 19 (56%) 11 (65%) 8 (47%) 0.30
  Mutant 15 (44%) 6 (35%) 9 (53%)
KRAS mutation type Codon 12 14 (93%) 6 (100%) 8 (89%) 0.40
  Codon 13 1 (7%) 0 1 (11%)
PFS (months) Median (range) 11.0 (2.3-39.8) 22.5 (14.8-39.8) 6.0 (2.3-7.2) s<0.0001
  1. Abbreviations: PS = performance status, PFS = progression-free survival.